192 related articles for article (PubMed ID: 27965306)
1. Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2
Lowenfeld L; Mick R; Datta J; Xu S; Fitzpatrick E; Fisher CS; Fox KR; DeMichele A; Zhang PJ; Weinstein SP; Roses RE; Czerniecki BJ
Clin Cancer Res; 2017 Jun; 23(12):2961-2971. PubMed ID: 27965306
[No Abstract] [Full Text] [Related]
2. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
3. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
Fracol M; Datta J; Lowenfeld L; Xu S; Zhang PJ; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Feb; 24(2):407-417. PubMed ID: 27663569
[TBL] [Abstract][Full Text] [Related]
4. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.
Fracol M; Xu S; Mick R; Fitzpatrick E; Nisenbaum H; Roses R; Fisher C; Tchou J; Fox K; Zhang P; Czerniecki BJ
Ann Surg Oncol; 2013 Oct; 20(10):3233-9. PubMed ID: 23851609
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
6. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
7. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
8. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 CD4
De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
[TBL] [Abstract][Full Text] [Related]
11. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER
Lowenfeld L; Zaheer S; Oechsle C; Fracol M; Datta J; Xu S; Fitzpatrick E; Roses RE; Fisher CS; McDonald ES; Zhang PJ; DeMichele A; Mick R; Koski GK; Czerniecki BJ
Oncoimmunology; 2017; 6(9):e1207032. PubMed ID: 28932627
[TBL] [Abstract][Full Text] [Related]
12. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
De La Cruz LM; Nocera NF; Czerniecki BJ
Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
14. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
15. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G; Kodumudi K; Snyder C; Grover P; Zhang H; Greene MI; Basu A; Gallen C; Wiener D; Costa RLB; Han HS; Koski G; Czerniecki BJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710296
[TBL] [Abstract][Full Text] [Related]
17. HER2 dendritic cell vaccines.
Morse MA; Clay TM; Colling K; Hobeika A; Grabstein K; Cheever MA; Lyerly HK
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S164-72. PubMed ID: 12620155
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
20. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.
Koski GK; Koldovsky U; Xu S; Mick R; Sharma A; Fitzpatrick E; Weinstein S; Nisenbaum H; Levine BL; Fox K; Zhang P; Czerniecki BJ
J Immunother; 2012 Jan; 35(1):54-65. PubMed ID: 22130160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
